Clinical Trials Logo

Cancer of the Prostate clinical trials

View clinical trials related to Cancer of the Prostate.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04541225 Terminated - Breast Cancer Clinical Trials

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Start date: December 8, 2020
Phase: Phase 1
Study type: Interventional

At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422. The study population comprised adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients self-administered NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT02640534 Terminated - Prostate Cancer Clinical Trials

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Start date: June 10, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to test if the combination of enzalutamide and metformin in patients with castration resistant prostate cancer CRPC progressing on androgen deprivation therapy ADT is more effective compared to enzalutamide alone. The half of the patients will receive the experimental treatment combination, enzalutamide and metformin, while the other half will receive enzalutamide alone.

NCT ID: NCT02349386 Terminated - Clinical trials for Cancer of the Prostate

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

MASTERS
Start date: July 2015
Phase: Phase 2
Study type: Interventional

The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with advanced androgen-sensitive prostate cancer.

NCT ID: NCT02349139 Terminated - Prostate Cancer Clinical Trials

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Start date: January 19, 2015
Phase: Phase 1
Study type: Interventional

This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001 through blood sampling. Subjects in Part B will receive one of two doses identified in Part A to determine which one is more effective, and collect additional pharmacokinetic data. Part C is an extension for subjects completing either Part A or B.